Corrigendum to: Primary human papillomavirus DNA screening for cervical cancer prevention: Can the screening interval be safelyextended? (Int J Cancer, (2015), 137, 2, (420-7), 10.1002/ijc.29381);Primary human papillomavirus DNA screening for cervical cancer prevention: Can the screening interval be safely extended?

International Journal of Cancer

Volumn 137, Issue 2, 2015, Pages 420-427

  Vink, Margaretha A ^a,b   Bogaards, Johannes A ^a   Meijer, Chris J L M ^b   Berkhof, Johannes ^b  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

cervical cancer; human papillomavirus DNA test; mass screening

Indexed keywords

VIRUS DNA;

ADULT; AGE; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; PAPILLOMAVIRUS INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; GENETICS; HOST PATHOGEN INTERACTION; INCIDENCE; MASS SCREENING; MIDDLE AGED; NETHERLANDS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PHYSIOLOGY; PROCEDURES; REPRODUCIBILITY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TIME; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ADULT; AGE FACTORS; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; FEMALE; FOLLOW-UP STUDIES; HOST-PATHOGEN INTERACTIONS; HUMANS; INCIDENCE; MASS SCREENING; MIDDLE AGED; NETHERLANDS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 84929288703     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.31230     Document Type: Erratum

References (36)

1. Anttila A, Ronco G, Clifford G, et al. Cervical cancer screening programmes and policies in 18 European countries. Br J Cancer 2004; 91: 935-41.
2. Quinn M, Babb P, Jones J, et al. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 1999; 318: 904-8.
3. Peto J, Gilham C, Deacon J, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 2004; 91: 942-53.
4. van der Aa MA, Pukkala E, Coebergh JW, et al. Mass screening programmes and trends in cervical cancer in Finland and the Netherlands. Int J Cancer 2008; 122: 1854-8.
5. Vink MA, Bogaards JA, van Kemenade FJ, et al. Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly censored national registry data. Am J Epidemiol 2013; 178: 1161-9.
6. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008; 9: 425-34.
7. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095-101.
8. Koliopoulos G, Arbyn M, Martin-Hirsch P, et al. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol 2007; 104: 232-46.
9. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012; 13: 78-88.
10. Ronco G, Dillner J, Elfstrom KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014; 383: 524-32.
11. Goldhaber-Fiebert JD, Stout NK, Salomon JA, et al. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16, 18 vaccination. J Natl Cancer Inst 2008; 100: 308-20.
12. Berkhof J, Coupe VM, Bogaards JA, et al. The health and economic effects of HPV DNA screening in The Netherlands. Int J Cancer 2010; 127: 2147-58.
13. van Rosmalen J, de Kok IM, van Ballegooijen M,. Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing. BJOG 2012; 119: 699-709.
14. National Institute for Public Health and the Environment (RIVM), Feasibility study for improvements to the population screening for cervical cancer [in Dutch], 2013.
15. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008; 337: a1754.
16. Kitchener HC, Gilham C, Sargent A, et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer 2011; 47: 864-71.
17. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011; 12: 663-72.
18. Elfstrom KM, Smelov V, Johansson AL, et al. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. BMJ 2014; 348: g130.
19. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370: 1764-72.
20. Coupé VM, Berkhof J, Bulkmans NW, et al. Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer 2008; 98: 646-51.
21. Bogaards JA, Xiridou M, Coupe VM, et al. Model-based estimation of viral transmissibility and infection-induced resistance from the age-dependent prevalence of infection for 14 high-risk types of human papillomavirus. Am J Epidemiol 2010; 171: 817-25.
22. Bulkmans NW, Rozendaal L, Snijders PJ, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004; 110: 94-101.
23. Bulk S,. The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol 2004; 57: 388-93.
24. Casparie M, Tiebosch AT, Burger G, et al. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 2007; 29: 19-24.
25. Anderson MC,. Premalignant and malignant squamous lesions of the cervix. In:, Fox H, Wells M, Haines M, Taylor C, eds. Obstetrical and gynaecological pathologyed. New York: Churchill Livinigstone, 1995. 292-7.
26. Straatman H, Peer PGM, Verbeek ALM,. Estimating lead time and sensitivity in a screening program without estimating the incidence in the screened group. Biometrics 1997; 53: 219-29.
27. Bulk S, Bulkmans NW, Berkhof J, et al. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. Int J Cancer 2007; 121: 361-7.
28. Dijkstra MG, van Niekerk D, Rijkaart DC, et al. Primary hrHPV DNA testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy. Cancer Epidemiol Biomarkers Prev 2014; 23: 55-63.
29. Rijkaart DC, Berkhof J, van Kemenade FJ, et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 2012; 130: 602-10.
30. van den Akker-van Marle ME, van Ballegooijen M, van Oortmarssen GJ, et al. Cost-effectiveness of cervical cancer screening: comparison of screening policies. J Natl Cancer Inst 2002; 94: 193-204.
31. Efron B, Tibshirani RJ,. An introduction to the bootstraped. London: Chapman & Hall, 1993.
32. Rijkaart DC, Berkhof J, van Kemenade FJ, et al. HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications. Br J Cancer 2012; 106: 975-81.
33. Comprehensive cancer centre the Netherlands (IKNL). Cervical Intraepithelial Neoplasia (CIN), National guidelines, Version: 1.1 [in Dutch], 2004.
34. Myers ER, McCrory DC, Nanda K, et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000; 151: 1158-71.
35. Kim JJ, Kuntz KM, Stout NK, et al. Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol 2007; 166: 137-50.
36. Insinga RP, Dasbach EJ, Elbasha EH,. Epidemiologic natural history and clinical management of human papillomavirus (HPV) disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis 2009; 9: 119.